Aldeyra Therapeutics, Inc (NASDAQ:ALDX - Get Free Report) major shareholder Perceptive Advisors Llc bought 8,374 shares of the firm's stock in a transaction on Monday, April 1st. The stock was purchased at an average price of $3.25 per share, with a total value of $27,215.50. Following the completion of the acquisition, the insider now owns 8,601,960 shares of the company's stock, valued at $27,956,370. The purchase was disclosed in a filing with the SEC, which is available through this link. Major shareholders that own more than 10% of a company's shares are required to disclose their transactions with the SEC.
Perceptive Advisors Llc also recently made the following trade(s):
- On Wednesday, April 3rd, Perceptive Advisors Llc purchased 309,847 shares of Aldeyra Therapeutics stock. The shares were bought at an average price of $4.09 per share, with a total value of $1,267,274.23.
Aldeyra Therapeutics Stock Performance
Shares of ALDX opened at $4.15 on Thursday. The firm has a market cap of $244.44 million, a PE ratio of -6.48 and a beta of 1.51. The firm's 50 day moving average price is $3.34 and its 200 day moving average price is $3.42. Aldeyra Therapeutics, Inc has a twelve month low of $1.42 and a twelve month high of $11.97.
Aldeyra Therapeutics (NASDAQ:ALDX - Get Free Report) last released its quarterly earnings results on Thursday, March 7th. The biotechnology company reported ($0.08) EPS for the quarter, beating analysts' consensus estimates of ($0.21) by $0.13. On average, sell-side analysts anticipate that Aldeyra Therapeutics, Inc will post -0.26 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Aldeyra Therapeutics
Elon’s New A.I. Device is About to Shock the World
From InvestorPlace | Ad
Using this device you see above…
Elon Musk just tested a new type of A.I. that according to Wired Magazine will usher in…
“The next step in human evolution.”
Click here to see the details because there’s a lot of money at stake.
A number of institutional investors have recently modified their holdings of the company. Vanguard Group Inc. raised its position in shares of Aldeyra Therapeutics by 23.2% in the fourth quarter. Vanguard Group Inc. now owns 3,927,597 shares of the biotechnology company's stock valued at $13,786,000 after purchasing an additional 740,177 shares during the period. BlackRock Inc. increased its position in Aldeyra Therapeutics by 228.0% during the second quarter. BlackRock Inc. now owns 3,230,414 shares of the biotechnology company's stock worth $27,103,000 after acquiring an additional 2,245,432 shares during the period. State Street Corp increased its position in Aldeyra Therapeutics by 1,655.5% during the second quarter. State Street Corp now owns 3,041,866 shares of the biotechnology company's stock worth $25,521,000 after acquiring an additional 2,868,585 shares during the period. Knoll Capital Management LLC increased its position in Aldeyra Therapeutics by 45.9% during the second quarter. Knoll Capital Management LLC now owns 3,015,668 shares of the biotechnology company's stock worth $25,301,000 after acquiring an additional 948,508 shares during the period. Finally, Verition Fund Management LLC increased its position in Aldeyra Therapeutics by 54.1% during the first quarter. Verition Fund Management LLC now owns 2,105,907 shares of the biotechnology company's stock worth $9,361,000 after acquiring an additional 739,206 shares during the period. Institutional investors own 59.71% of the company's stock.
Wall Street Analyst Weigh In
Several research firms recently commented on ALDX. HC Wainwright restated a "buy" rating and set a $10.00 price target on shares of Aldeyra Therapeutics in a report on Tuesday. StockNews.com raised shares of Aldeyra Therapeutics from a "sell" rating to a "hold" rating in a research report on Monday, January 29th. Finally, Oppenheimer raised shares of Aldeyra Therapeutics from a "market perform" rating to an "outperform" rating and set a $10.00 price objective on the stock in a research report on Wednesday.
Check Out Our Latest Research Report on Aldeyra Therapeutics
About Aldeyra Therapeutics
(
Get Free Report)
Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company’s lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
